L. Endang Budiarti, L. Endang
Pharmacy Instalation, Bethesda Hospital, Yogyakarta, Indonesia.

Published : 5 Documents
Articles

Found 5 Documents
Search

Evaluation of antibiotic usage in patient with fever in a private hospital in Yogyakarta (period January – June 2002) Widayati, Aris; Budiarti, L. Endang; Donatus, Imono Argo
INDONESIAN JOURNAL OF PHARMACY Vol 15 No 3, 2004
Publisher : Faculty of Pharmacy Universitas Gadjah Mada, Yogyakarta, Skip Utara, 55281, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (271.798 KB) | DOI: 10.14499/indonesianjpharm0iss0pp144-150

Abstract

Fever as a symptom may indicate to any other diseases. According to the standard therapy by IDI (1998) fever should be treated without antibiotic, but the fact showed that 70 % antibiotics were used for treatment. This study aimed at describing about fever and evaluating antibiotic usage in patients with fever as a final diagnose by appropriateness, effectiveness, and safety as a criteria of evaluation.The present study was done with retrospective data collection and descriptive-evaluative design. Data was collected from medical records within a period from 2002 January to June. A number of 157 patients were used for the assesment.The highest percentage of patient’s fever was a group of 17 – 60 years old (63. 28%). The final diagnose was fever (29.58%) and others (70.42%) such as viral infection (17.16%), DHF (8.28%), DF (7.01%) and acute respiratory traction infection (5.92%). There were 29 kinds of antibiotics (79.62%) that given to the patients as an empirical therapy and the highest was pefloxacin (13.14%). The percentage of antibiotic usage in patients with fever as a final diagnose (50 patients) was 86.00% (21 kinds of antibiotics) and the highest was pefloxacin (17.19%). Both of fever less than 5 days ormore than 5 days were treated with antibiotic, which was inappropriate usage because fever less than 5 days related to viral infection. There was only 4.65% had a culture and sensitivity test, which was appropriate antibiotics usage. There were 46.51% no growth of culture and 48.84% without culture, which was inappropriate antibiotics usage. Treatment with and without antibiotics could normalize vital signs each was 90.70% and 85.71% with no significant difference (with non parametric exact probability Fisher analysis, CI 0.05) and RR value (95%, 0.69-1.30). Patient’s recoveries were 88.37% and 85.71% with and without antibiotic therapy with no significant difference (CI 95% and 0.96 RR value with CI 95%; 0.66 – 1.41). There were two cases (4.00%) of contraindication and 12.00% of potential drug interactions. According to the standard therapy and supporting data of this study, so that fever should not always be treated with antibiotic.Key words: antibiotic, fever, evaluation.
Effectifity and Cost Analysis of Omeprazole and Pantoprazole for Stress Related Mucosal Disease Prophylaxis in ICU Sukengtyas, Dyah Atmi Tri; Andayani, Tri Murti; Budiarti, L. Endang
JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice) Vol 7, No 2
Publisher : Faculty of Pharmacy, Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/jmpf.30119

Abstract

Currently, the most effective therapeutic agent as a Stress Related Mucosal Disease (SRMD) prophylaxis therapy is the group of Proton Pump Inhibitor (PPI). In Indonesia, PPI agent most commonly used is pantoprazole and omeprazole, for they are already available in the form of injection and also available in generic product. This study aimed to determine the effectiveness and the therapy cost of omeprazole and pantoprazole used as a prophylaxis agent of SRMD. This study used observational analytic method using a retrospective cohort study. The subjects were patients in ICU of Bethesda Hospital in Yogyakarta with age ≥ 18 year old who received the therapy of omeprazole or pantoprazole as a prophylaxis of SRMD during January 2012 – September 2016 who meet the inclusion and exclusion criteria. The effectivity of therapy was seen by the bleeding events. The cost was calculated based on the amount of fee required by the patient, both the use of the medicine as a prophylaxis therapy of SRMD and for the bleeding therapy of SRMD. The value of Expected Monetary Value (EMV) was then calculated using the method of Decision Tree. Subject in this study were 152 patients, in which there were 76 patients on each group therapy of pantoprazole and omeprazole. The comparison between the number of patients who did not experience bleeding between group of pantoprazole and group of omeprazole is 85.5%: 81.6% (p = 0.512). The value of EMV in the pantoprazole group is Rp. 431.490,76, while the omeprazole group is Rp. 382.042,57. There is no difference in the effectivity between pantoprazole and omeprazole as a prophylaxis of SRMD, and the cost for SRMD prophylaxis is cheaper in the omeprazole therapy than in the pantoprazole therapy.
COST OF ILLNESS DARI CHRONIC KIDNEY DISEASE DENGAN TINDAKAN HEMODIALISIS Fauziah, Fauziah; Wahyono, Djoko; Budiarti, L. Endang
JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice) Vol 5, No 3
Publisher : Faculty of Pharmacy, Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/jmpf.226

Abstract

Hemodialisis (HD) atau cuci darah sangat berperan penting bagi penderita gagal ginjal. Proses hemodialisis merupakan tindakan pengobatan yang mahal dan akan menjadi beban berat bagi pasien yang melakukan tindakan hemodialisis berulang kali selama seumur hidupnya. Tujuan penelitian adalah mengetahui total biaya penyakit Chronic Kidney Disease (CKD) dan untuk mengetahui perbedaan faktor pasien, faktor penyakit, dan faktor jenis pembiayaan terhadap biaya medik langsung pada pasien CKD dengan tindakan hemodialisis rawat jalan dan rawat inap. Jenis penelitian menggunakan rancangan penelitian deskriptif analitik menurut perspektif rumah sakit. Pengambilan data dilakukan secara retrospektif dengan melihat rekam medis pasien yang melakukan hemodialisis pada periode Januari sampai Juni 2014 di Rumah Sakit Bethesda Yogyakarta. Variabel terikat (dependent variable) adalah total biaya medik langsung pasien rawat inap dan rawat jalan yang melakukan tindakan hemodialisis di Rumah sakit Bethesda Yogyakarta, sedangkan variabel bebas (independent variable) adalah faktor pasien, faktor penyakit, dan faktor jenis pembiayaan. Analisis statistik yang digunakan adalah statistik deskriptif, distribusi varian, uji Mann-Whitney, dan uji Kruskal-Wallis. Hasil penelitian menunjukkan bahwa pasien CKD dengan tindakan hemodialisis yang masuk kriteria inklusi sebanyak 104 pasien dengan 1.861 episode rawat jalan dan 31 episode rawat inap. Cost of illness pasien CKD dengan tindakan hemodialisis sebesar Rp. 2.295.068.531,00. Pada pasien rawat jalan terdapat perbedaan total biaya medik langsung pada faktor jenis kelamin, usia, jenis komorbid, dan frekuensi hemodialisis. Pada pasien rawat inap, tidak ada perbedaan antara faktor tersebut terhadap total biaya medik langsung.Kata kunci: cost of illness, penyakit ginjal kronik, hemodialisis
COST OF ILLNESS DARI CHRONIC KIDNEY DISEASE DENGAN TINDAKAN HEMODIALISIS Fauziah, Fauziah; Wahyono, Djoko; Budiarti, L. Endang
JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice) Vol 5, No 3
Publisher : Faculty of Pharmacy, Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (1340.935 KB) | DOI: 10.22146/jmpf.226

Abstract

Hemodialisis (HD) atau cuci darah sangat berperan penting bagi penderita gagal ginjal. Proses hemodialisis merupakan tindakan pengobatan yang mahal dan akan menjadi beban berat bagi pasien yang melakukan tindakan hemodialisis berulang kali selama seumur hidupnya. Tujuan penelitian adalah mengetahui total biaya penyakit Chronic Kidney Disease (CKD) dan untuk mengetahui perbedaan faktor pasien, faktor penyakit, dan faktor jenis pembiayaan terhadap biaya medik langsung pada pasien CKD dengan tindakan hemodialisis rawat jalan dan rawat inap. Jenis penelitian menggunakan rancangan penelitian deskriptif analitik menurut perspektif rumah sakit. Pengambilan data dilakukan secara retrospektif dengan melihat rekam medis pasien yang melakukan hemodialisis pada periode Januari sampai Juni 2014 di Rumah Sakit Bethesda Yogyakarta. Variabel terikat (dependent variable) adalah total biaya medik langsung pasien rawat inap dan rawat jalan yang melakukan tindakan hemodialisis di Rumah sakit Bethesda Yogyakarta, sedangkan variabel bebas (independent variable) adalah faktor pasien, faktor penyakit, dan faktor jenis pembiayaan. Analisis statistik yang digunakan adalah statistik deskriptif, distribusi varian, uji Mann-Whitney, dan uji Kruskal-Wallis. Hasil penelitian menunjukkan bahwa pasien CKD dengan tindakan hemodialisis yang masuk kriteria inklusi sebanyak 104 pasien dengan 1.861 episode rawat jalan dan 31 episode rawat inap. Cost of illness pasien CKD dengan tindakan hemodialisis sebesar Rp. 2.295.068.531,00. Pada pasien rawat jalan terdapat perbedaan total biaya medik langsung pada faktor jenis kelamin, usia, jenis komorbid, dan frekuensi hemodialisis. Pada pasien rawat inap, tidak ada perbedaan antara faktor tersebut terhadap total biaya medik langsung.Kata kunci: cost of illness, penyakit ginjal kronik, hemodialisis
Effectifity and Cost Analysis of Omeprazole and Pantoprazole for Stress Related Mucosal Disease Prophylaxis in ICU Sukengtyas, Dyah Atmi Tri; Andayani, Tri Murti; Budiarti, L. Endang
JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice) Vol 7, No 2
Publisher : Faculty of Pharmacy, Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (1090.923 KB) | DOI: 10.22146/jmpf.30119

Abstract

Currently, the most effective therapeutic agent as a Stress Related Mucosal Disease (SRMD) prophylaxis therapy is the group of Proton Pump Inhibitor (PPI). In Indonesia, PPI agent most commonly used is pantoprazole and omeprazole, for they are already available in the form of injection and also available in generic product. This study aimed to determine the effectiveness and the therapy cost of omeprazole and pantoprazole used as a prophylaxis agent of SRMD. This study used observational analytic method using a retrospective cohort study. The subjects were patients in ICU of Bethesda Hospital in Yogyakarta with age ≥ 18 year old who received the therapy of omeprazole or pantoprazole as a prophylaxis of SRMD during January 2012 – September 2016 who meet the inclusion and exclusion criteria. The effectivity of therapy was seen by the bleeding events. The cost was calculated based on the amount of fee required by the patient, both the use of the medicine as a prophylaxis therapy of SRMD and for the bleeding therapy of SRMD. The value of Expected Monetary Value (EMV) was then calculated using the method of Decision Tree. Subject in this study were 152 patients, in which there were 76 patients on each group therapy of pantoprazole and omeprazole. The comparison between the number of patients who did not experience bleeding between group of pantoprazole and group of omeprazole is 85.5%: 81.6% (p = 0.512). The value of EMV in the pantoprazole group is Rp. 431.490,76, while the omeprazole group is Rp. 382.042,57. There is no difference in the effectivity between pantoprazole and omeprazole as a prophylaxis of SRMD, and the cost for SRMD prophylaxis is cheaper in the omeprazole therapy than in the pantoprazole therapy.